🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

The Affiliated Hospital of Xuzhou Medical University clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with The Affiliated Hospital of Xuzhou Medical University as lead sponsor. Synced 26 Sep 2026
24Current trials
16Recruiting now
9Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

The Affiliated Hospital of Xuzhou Medical University is the lead sponsor of 24 current clinical trials in our China register. 16 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Cyclophosphamide, Fludarabine and Tislelizumab. The most-studied condition is Immunotherapy.

ClinicalTrials.gov trials by status

  • Recruiting1667%
  • Not yet open417%
  • Active, closed417%

Trials by phase

  • Not applicable729%
  • Observational625%
  • Phase 1313%
  • Phase 2313%
  • Phase EARLY_PHASE128%
  • Phase 414%
  • Phase 314%
  • Phase 1/214%
01

Clinical trials sponsored by The Affiliated Hospital of Xuzhou Medical University

24 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Surgical-imaging Research on Obesity (SIRO)
NCT06268262 · ClinicalTrials.gov ↗ · Overweight and Obesity
Observational Recruiting 2023-03 China
Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer
NCT05354375 · ClinicalTrials.gov ↗ · Immunotherapy
Phase 1 Recruiting 2022-12 China
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
NCT07058103 · ClinicalTrials.gov ↗ · Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory
Phase 2 Recruiting 2025-04 China
Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma
NCT04969354 · ClinicalTrials.gov ↗ · Immunotherapy
Phase 1 Recruiting 2021-10 China
Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL
NCT07120633 · ClinicalTrials.gov ↗ · CLL, CAR-T Cell Therapy, SLL
Not applicable Recruiting 2025-09 China
Predictive Role of sTREM in Endovascular Thrombectomy Outcomes
NCT06545591 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke
Observational Recruiting 2024-07 China
Establishment of an Early Warning Screening System for Hemophagocytic Lymphohistiocytosis a Multi-center, Prospective Study
NCT06614998 · ClinicalTrials.gov ↗ · Hemophagocytic Syndrome
Observational Recruiting 2024-05 China
Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM
NCT06256419 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus, Susceptibility, Genetic
Not applicable Recruiting 2024-01 China
Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
NCT07413835 · ClinicalTrials.gov ↗ · Refractory Myasthenia Gravis
Drug: HN2302
Not applicable Recruiting 2026-03 China
BGT007H Cells for the Treatment of Refractory Digestive System Tumors
NCT06104215 · ClinicalTrials.gov ↗ · Digestive Tract Cancer
Phase EARLY_PHASE1 Recruiting 2023-10 China
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL
NCT07168317 · ClinicalTrials.gov ↗ · New Diagnosed Angioimmunoblastic T-Cell Lymphoma
Phase 2 Recruiting 2025-08 China
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
NCT07285395 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Drug: SBRT
Phase 1 Recruiting 2025-11 China
Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
NCT07680933 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma
Phase 2 Recruiting 2026-03 China
Effect of Mutations in T2DM Susceptibility Genes on the Expression of Susceptibility Genes in Patients With T2DM and Controls
NCT06277466 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus, Gene Polymorphisms, Genetic Mutations
Not applicable Recruiting 2024-01 China
BGT007 Cells for the Treatment of Refractory Digestive System Tumors
NCT06104241 · ClinicalTrials.gov ↗ · Gastrointestinal Cancer
Phase EARLY_PHASE1 Recruiting 2023-10 China
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
NCT05323201 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
Phase 1/2 Recruiting 2022-02 China
Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients
NCT06683131 · ClinicalTrials.gov ↗ · Acute Myocardial Infarction (AMI)
Phase 4 Not yet open 2025-11 China
A Prospective Study on IVUS and DSA Guidance in the Treatment of Budd-Chiari Syndrome
NCT06960473 · ClinicalTrials.gov ↗ · Budd-Chiari Syndrome
Not applicable Not yet open 2025-05 China
Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
NCT07034755 · ClinicalTrials.gov ↗ · Multiple Myeloma (MM), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), Chimeric Antigen Receptor T-cell
Not applicable Not yet open 2025-07 China
High-Frequency QRS for Predicting Microvascular Dysfunction and Adverse Events After PCI in Acute Myocardial Infarction
NCT07138638 · ClinicalTrials.gov ↗ · AMI
Observational Not yet open 2025-08 China
Heart Failure With Preserved Ejection Fraction and Its Cardiac MR Characteristics of Different Subtypes
NCT06916611 · ClinicalTrials.gov ↗ · HFpEF, Heart Failure With Preserved Ejection Fraction
Observational Active, closed 2023-05 China
To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy
NCT07098897 · ClinicalTrials.gov ↗ · IgA Nephropathy (IgAN)
Phase 3 Active, closed 2024-08 China
Early CMR in Acute MI
NCT07602439 · ClinicalTrials.gov ↗ · Acute Myocardial Infarction (AMI)
Observational Active, closed 2018-10 China
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
NCT07155369 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus, Systemic Sclerosis
Not applicable Active, closed 2025-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in The Affiliated Hospital of Xuzhou Medical University trials

9 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in The Affiliated Hospital of Xuzhou Medical University trials

31 conditions
Immunotherapy2Acute Myocardial Infarction (AMI)2Type 2 Diabetes Mellitus2Susceptibility, Genetic2HFpEF1Heart Failure With Preserved Ejection Fraction1Overweight and Obesity1Angioimmunoblastic T-Cell Lymphoma Recurrent1Angioimmunoblastic T-Cell Lymphoma Refractory1Budd-Chiari Syndrome1CLL1CAR-T Cell Therapy1SLL1Acute Ischemic Stroke1Hemophagocytic Syndrome1Refractory Myasthenia Gravis1Digestive Tract Cancer1Multiple Myeloma (MM)1Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)1Chimeric Antigen Receptor T-cell1IgA Nephropathy (IgAN)1New Diagnosed Angioimmunoblastic T-Cell Lymphoma1Advanced Solid Tumors1DLBCL - Diffuse Large B Cell Lymphoma1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2416

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Immunotherapy

SponsorTrials
West China Hospital6
Nanfang Hospital, Southern Medical University4
Elephas2
Hubei Cancer Hospital2
Fujian Medical University Union Hospital2
Tao Zhang2
Guangzhou FineImmune Biotechnology2

Sponsors with the most current trials registered for this condition.

06

Questions about The Affiliated Hospital of Xuzhou Medical University trials

How many clinical trials does The Affiliated Hospital of Xuzhou Medical University sponsor?

The Affiliated Hospital of Xuzhou Medical University is the lead sponsor of 24 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are The Affiliated Hospital of Xuzhou Medical University trials recruiting?

Yes. 16 of its 24 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is The Affiliated Hospital of Xuzhou Medical University testing?

Its current trials name 9 drugs and biologicals as interventions. The most frequent are Cyclophosphamide (2), Fludarabine (2), Tislelizumab (2), Cytoxan (1) and Fludara (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.